Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells

Current Pharmaceutical Design

Volumn 20, Issue 11, 2014, Pages 1881-1887

  Xu, Shaohua ^a   Ren, Juan ^b   Chen, Hai Bin ^c   Wang, Yanlin ^d   Liu, Qingyou ^e   Zhang, Run ^f,g   Jiang, Shi Wen ^f,h   Li, Jinping ^f  

^a Nanjing Medical University   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^c SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^d BINZHOU MEDICAL UNIVERSITY HOSPITAL   (China)

^e GUANGXI UNIVERSITY   (China)

^f MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^h Memorial Health   (United States)

Author keywords

Apoptosis; Cell cycle; DNMT inhibitor; Endometrial cancer; HDAC inhibitor

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOSTATIC AGENT; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; PROTEIN P15; PROTEIN P21; ANTINEOPLASTIC AGENT; AZACITIDINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DNA REPAIR; ENDOMETRIAL CANCER CELL LINE; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTINUCLEAR CELL; PRIORITY JOURNAL; SINGLE STRANDED DNA BREAK; UPREGULATION; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CELL CYCLE; DNA METHYLATION; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; ENZYMOLOGY; FEMALE; GENETIC EPIGENESIS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; NEOPLASM STAGING;

EID: 84903748276     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990527     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Cady B. Lymph node metastases. Indicators, but not governors of survival. Arch Surg 1984; 119: 1067-72.
3. Inoue Y, Obata K, Abe K, et al. The prognostic significance of vascular invasion by endometrial carcinoma. Cancer 1996; 78: 1447-51.
4. Mariani A, Webb MJ, Keeney GL, et al. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol 2002; 84: 437-42.
5. Mariani A, Dowdy SC, Cliby WA, et al. Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol Oncol 2006; 101: 200-8.
6. Zysman M, Saka A, Millar A, et al. Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype. Cancer Res 2002; 62: 3663-6.
7. Kim GE, Kweon SS, Lee JS, et al. Quantitative assessment of DNA methylation for the detection of cervical and endometrial adenocarcinomas in liquid-based cytology specimens. Anal Quant Cytol Histol 2012; 34: 195-203.
8. Dowdy SC, Gostout BS, Shridhar V, et al. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol 2005; 99: 126-34.
9. Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001; 91: 22-6.
10. Esteller M, Catasus L, Matias-Guiu X, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999; 155: 1767-72.
11. Strathdee G, MacKean MJ, Illand M, et al. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999; 18: 2335-41.
12. Sasaki M, Kaneuchi M, Fujimoto S, et al. Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers. Mol Cell Endocrinol 2003; 202: 201-7.
13. Hanekamp EE, Gielen SC, Smid-Koopman E, et al. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 2003; 9: 4190-9.
14. Ehrlich CE, Young PC, Cleary RE. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. Am J Obstet Gynecol 1981; 141: 539-46.
15. Dobosy JR, Selker EU. Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 2001; 58: 721-7.
16. Choi CH, Burton ZF, Usheva A. Auto-acetylation of transcription factors as a control mechanism in gene expression. Cell Cycle 2004; 3: 114-5.
17. Halkidou K, Gaughan L, Cook S, et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59: 177-89.
18. Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004; 112: 26-32.
19. Serrador JM, Cabrero JR, Sancho D, et al. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 2004; 20: 417-28.
20. Weichert W, Denkert C, Noske A, et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 2008; 10: 1021-7.
21. Singh KP, Treas J, Tyagi T, et al. DNA demethylation by 5-aza-2-deoxycytidine treatment abrogates 17 beta-estradiol-induced cell growth and restores expression of DNA repair genes in human breast cancer cells. Cancer Lett 2012; 316: 62-9.
22. Xiong Y, Dowdy SC, Gonzalez Bosquet J, et al. Epigeneticmediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol 2005; 99: 135-41.
23. Jiang S, Dowdy SC, Meng XW, et al. Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells. Gynecol Oncol 2007; 105: 493-500.
24. Takai N, Ueda T, Nishida M, et al. CBHA is a family of hybrid polar compounds that inhibit histone deacetylase, and induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Oncology 2006; 70: 97-105.
25. Takai N, Ueda T, Nishida M, et al. M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. Gynecol Oncol 2006; 101: 108-13.
26. Takai N, Ueda T, Nishida M, et al. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. Int J Mol Med 2006; 17: 323-9.
27. Hitomi T, Matsuzaki Y, Yokota T, et al. p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Lett 2003; 554: 347-50.
28. Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999; 27: 2291-8.
29. Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97: 1172-9.
30. Jin F, Dowdy SC, Xiong Y, et al. Up-regulation of DNA methyltransferase 3B expression in endometrial cancers. Gynecol Oncol 2005; 96: 531-8.
31. Mathew OP, Ranganna K, Yatsu FM. Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells. Biomed Pharmacother 2010; 64: 733-40.
32. Gui CY, Ngo L, Xu WS, et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoterassociated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 1241-6.
33. Singh BN, Zhang G, Hwa YL, et al. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 2010; 10: 935-54.
34. Bieliauskas AV, Pflum MK. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 2008; 37: 1402-13.
35. Rosato RR, Almenara JA, Dai Y, et al. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003; 2: 1273-84.